- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Cinthya Pena Orbea Discusses Socioeconomic Impacts on Sleep-Disordered Breathing
Many socioeconomic factors, such as neighborhood factors, access to care, and education can influence sleep, explained Cinthya Pena Orbea, MD, assistant professor of medicine, Cleveland Clinic.
At SLEEP 2022, Cinthya Pena Orbea, MD, assistant professor of medicine, Cleveland Clinic, discussed how socioeconomic factors can influence sleep-disordered breathing.
What did your study find about the relationship between socioeconomic status and sleep-disordered breathing?
There are many socioeconomic factors that can influence sleep, and that could be neighborhood factors, access to care, education. In our study, what we wanted to study is the association between ADI—which stands for area deprivation index, which is a biomarker of neighborhood socioeconomic disadvantage—the association of these and sleep disorder breathing measures. What we found was that sleep-related hypoxia was higher among those people living in higher areas of deprivation.
Infertility Coverage Boosts ART Use and Pregnancy Success: Richard A. Brook, MS, MBA
August 26th 2025In this episode, Richard A. Brook, MS, MBA, discusses his study showing that infertility treatment coverage increases assisted reproductive technology (ART) use and improves pregnancy outcomes.
Listen
Current and Emerging Options for Uncommon EGFR- and Exon 20 Insertion–Mutated NSCLC
September 8th 2025Uncommon EGFR mutations in non–small cell lung cancer (NSCLC) remain challenging to treat, but new tyrosine kinase inhibitors, bispecific antibodies, and a proposed “PACCage insert” framework provide opportunities to advance precision therapy.
Read More
Hope on the Horizon for Underserved Patients With Multiple Myeloma: Joseph Mikhael, MD
August 12th 2025Explore the disparities in multiple myeloma treatment and how new initiatives aim to improve clinical trial participation among underrepresented patients during a conversation with Joseph Mikhael, MD, MEd, FRCPC, FACP, FASCO, chief medical officer of the International Myeloma Foundation.
Listen
Evolving Roles of Antibody-Drug Conjugates in the Treatment of NSCLC
September 7th 2025Antibody-drug conjugates are rapidly reshaping the treatment landscape of non–small cell lung cancer (NSCLC), with advances in design, clinical efficacy, and regulatory approvals tempered by ongoing challenges in toxicity, resistance, and biomarker optimization.
Read More
From Amivantamab to Next-Generation Therapies: The Evolving Bispecific Antibody Landscape in NSCLC
September 6th 2025Bispecific antibodies are emerging as a transformative class in advanced non–small cell lung cancer (NSCLC), with agents such as amivantamab and zenocutuzumab already demonstrating clinical benefit and a broad pipeline of investigational therapies showing promise in overcoming resistance.
Read More
